pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·13h ago·1 min read
save

FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo

Eli Lilly’s once-weekly basal insulin shot Onswik has been approved by the FDA for patients with type 2 diabetes. Lilly has touted Onswik as a longer-acting alternative to daily basal insulin injections. It will compete ...

Sep 24, 2026·read at Endpoints ↗

September 24, 2026 12:16 PM EDT PharmaFDA+ FDA ap­proves Eli Lil­ly's once-week­ly in­sulin pen, set­ting up ri­val­ry with No­vo Nicole DeFeudis Senior Reporter Eli Lil­ly’s once-week­ly basal in­sulin shot On­swik has been ap­proved by the FDA for pa­tients with type 2 di­a­betes. Lil­ly has tout­ed On­swik as a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
83 words · retrieved 12h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY3ELI LILLY CO2NOVO
drugs
insulin3Type 2 Diabetes
topics
Type 2 Diabetes2

related stories

  • 16h agoEli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalryBioSpace
  • Sep 16'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandFierce Biotech
  • Aug 19Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?BioSpace
  • Jul 20Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceBioSpace
  • 3d agoNovo’s plan to hit $23B in revenue by 2035 leaves investors wantingBioSpace